SUBJECT INFORMED CONSENT TO PARTICIPATE IN A RESEARCH STUDY AND AUTHORIZATION FOR USE AND DISCLOSURE OF SUBJECT'S MEDICAL RECORDS AND INFORMATION

Title: A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Protocol No. CF111/303

Sponsor: Laboratorios León Farma S.A.
La Vallina s/n
Polígono Industrial de Navatejera
24008 Navatejera (León), Spain

Study Doctor Name: **Kurt Thomas Barnhart MD MSCE**

Research Site Address(es):

University of Pennsylvania
3701 Market St Ste 810
Philadelphia PA 19104

Daytime Telephone Number(s): 215-662-7727

24-hour Contact Number(s): 215-662-6100 (Ask for the Infertility Fellow on call)

Subject Number |__|__|__|__|__|__|

Introduction
You are being invited to take part in a clinical research study. Before you decide whether or not to take part in this study, it is important for you to understand why the research is being done and what it will involve. This consent form provides information about this study and your rights as a subject in clinical research, to help you make an informed decision about participating.

Please read this form carefully. You may discuss it with friends, family, or your personal doctor, if you wish. Please ask the study doctor or study staff if there is anything that is not clear or if you would like more information. Take time to decide whether or not you would like to take part in this study. If you agree to participate, you will be asked to sign this consent form.

Why is this study being done?
Clinical studies help increase knowledge on whether investigational drugs may be effective and safe. An “investigational” drug is an experimental drug that has not yet been approved by the Food and Drug Administration (FDA) to be sold in the United States.

You are being asked to participate in this research study because you are seeking contraception. Oral contraceptives (or birth control pills) are among the most popular types of contraception. There are two types of birth control pills: “combined” oral contraceptive pills (estrogen plus progestogen) and “progestogen-only” pills. Progestogen-only pills may be useful for women who should not take estrogens (for example, because of migraines, high blood pressure, high cholesterol levels, obesity, diabetes, or smoking habits) and for breastfeeding women. Women taking progestogen-only pills are more likely than women taking combined pills to have occasional breakthrough bleeding between periods (for example, spotting) and missed periods.

The investigational oral contraceptive that is being tested in this clinical research trial contains a type of progestogen called drospirenone (DRSP). DRSP is a synthetic progestogen that is similar to natural progesterone (the hormone involved in the female menstrual cycle). It is believed that DRSP may act in humans in a way similar to natural progesterone.

DRSP has been used in combination with estrogen in some oral contraceptives and in other drugs that have been approved by the FDA. However, the FDA has not approved DRSP to be used alone as an oral contraceptive. The study drug being tested in this clinical research trial is called LF111. Each tablet with active study drug contains 4 mg of DRSP, which will be taken for 13 cycles (for a total of about a year).

In previous clinical trials done in Europe, 1332 women have taken LF111. The results of these clinical trials suggest that LF111 is effective as a contraceptive. It has been proven that DRSP 4 mg administered 24 days followed by 4 days of placebo is able to inhibit ovulation, which prevents fertilization of an egg and its implantation in the uterus so that a pregnancy does not occur. A placebo is a drug that does not contain any active ingredients.

The purpose of this clinical research study is to find out how safe and effective LF111 may be as a contraceptive and how it affects women's menstrual bleeding patterns. It will also examine how long LF111 stays in women's bodies by testing samples of their blood. Women of childbearing potential who are 18 years of age or older may take part in this research study. Adolescents aged 15-17 years old may also take part in the research study with the permission of their parents or guardians.

The research study will be conducted at approximately 32 clinics located in the United States. It is planned that at least 750 women and adolescents will be included in the study. The research study is sponsored by the pharmaceutical company Laboratorios León Farma S.A. (Leon), which is based in Spain. Leon is being assisted by Health Decisions, a company based in the United States, and by Scope International AG, a company based in Germany. Your study doctor is being paid by Leon to conduct this study.

What is involved in the study?
Your study involvement will last up to approximately thirteen and a half months, and you will have eight visits to the study clinic. Your study doctor will inform you about the possible duration and timing of each visit. You will also be asked to use an electronic diary ("e-diary") to record daily information about taking the study drug, your menstrual cycles, the use of additional contraceptives, weekly information concerning your sexual activity, and whether you have experienced any changes in your health.

You will have a screening visit (Visit 1a) at the beginning. If you qualify for the study, you will have another visit (Visit 1b), when you will be given study drug and the electronic diary. You will take the study drug for 13 cycles of 28 days (approximately a year) and you will have at least five visits to the study clinic during that time. You will then have a final follow-up visit about two weeks after you stop taking the study drug.

You may be asked to come to the study clinic for additional visits if they are needed to complete study procedures or for safety or administrative reasons. The study staff may also contact you between visits to check how you are doing or to remind you about study visits or procedures.

You should not take part in this study if you may want to become pregnant during the time of the study.

Visit 1a (Screening)
During Visit 1a, the study doctor and staff will discuss the study with you and answer any questions that you have. You should ask any questions that you have about what is involved in taking part in the study. If you decide to take part in the study, you will be asked to sign this informed consent form. If you would like to take this form home and discuss the study with others before deciding to participate, you are free to do so. All examinations for the study will only be done after you have agreed to take part and have signed this consent form.

The study doctor or staff will check whether there is any medical or other reason that you should not participate. It is very important that you answer all questions about your medical history, your gynecological history, and any medications or supplements you are taking.

The study doctor or staff will:

- Measure your pulse rate, blood pressure, height, and weight.
- Perform a physical exam.
- Perform a gynecological examination, which will include:
    - A breast exam.
    - An external and internal examination of your genitals (which will include a speculum examination).
    - A transvaginal ultrasound.
    - Collection of a cervical smear (for a "Pap" test).
- Collection of a urine sample.
- Collection of about three teaspoons (approximately 15 ml) of blood samples for blood tests and a serum pregnancy test.

You have to stop using any other contraceptive methods during the study. There are some exceptions to this rule that are explained below.

Visit 1b

When the results of the screening laboratory tests are available and if you qualify to take part in the research study, you will come to the study clinic for Visit 1b. The study doctor or staff will measure your pulse rate, blood pressure, and weight. You will also have a urine pregnancy test.

The study doctor or staff will give you the first packs of study drug (for one cycle and one extra pack), one pregnancy test kit to be used at home before you take the very first pill, and the e-diary.

You will also be given a subject card that gives information about the study and includes contact information for the study doctor. **You should carry this subject card with you at all times** in case you need to contact the study doctor for an emergency and so you can show it to other doctors that you see, so they will know you are taking part in a clinical trial.

The study doctor or the site staff will explain how to use the e-diary and you will actively complete one training section. Starting on the day you begin taking the study drug, you should enter information in the study diary about the study drug tablets you have taken, any vaginal bleeding that you may have had, and any additional contraceptive methods that you have used. Once each week, the diary will also have a question about your sexual activity.

On the ninth day of each cycle, you will be asked in the e-diary if you have experienced any medical events and you will be contacted by the study doctor or site staff for additional information.

The e-diary will also remind you daily (except on Day 9) to contact your doctor if you feel unwell. **Please bring the e-diary to each clinic visit.**

Visit 2 through Visit 5 (Day 20 ± 2 of Cycle 1, 3, 6 and 9)

At Visit 2 through Visit 5, the study doctor or staff will measure your pulse rate, blood pressure, and weight and will perform a urine dipstick pregnancy test. You will be given a supply of study drug and pregnancy tests to be used at home at each visit.

You should keep all study drug packs (even if they are empty) and bring all of them back to the clinic at each visit for review or collection by the site staff.

At these visits, the study staff will check the entries you have made in your e-diary and may ask for more information. You will be asked if you have experienced any medical events, about any other medications or supplements that you have taken, and about the use of other contraceptives. At Visit 3 only, you will be asked by the study doctor how you are tolerating the study drug, i.e. if you are satisfied with your contraception and how you feel in comparison to how you felt while taking former contraceptives. At Visit 4 only, you will have a general physical exam and a gynecological exam. At Visit 5 only, your doctor will discuss with you your contraceptive options for the time after participation before you stop taking the study drug.

- Blood samples will be taken at these visits: At Visit 2 and Visit 4, two blood samples of approximately two teaspoons (10 ml) each will be taken to see how much of the study drug is in your blood. The two blood samples will be taken approximately one hour apart, with no study drug taken in between. You will be asked for the exact time you last took study drug before the visit.
- Additional blood samples of approximately three teaspoons (15 ml) each will be taken for laboratory tests at Visits 3 through 5. At Visit 2, a blood sample will only be taken if you take medications that may increase potassium blood levels.
- At Visit 4, you will be asked for a urine sample for additional laboratory tests (in addition to a pregnancy test).

Visit 6/Early Discontinuation (Day 29 + 2 of Cycle 13)

At Visit 6, the same examinations are planned that were done at the Screening Visit. Instead of a serum pregnancy test, you will have a urine pregnancy test. The doctor will check the entries you have made in your e-diary and collect the electronic diary device. You will be asked if you have experienced any medical events, about any other medications or supplements that you have taken, and about the use of other contraceptives. Additionally, you will be asked by the study doctor how you tolerate the study drug.

Please bring all study drug packs (both used and unused) with you to the clinic.

Visit 7 (Follow-up Visit) (10 to 14 days after V6)

At Visit 7, you will have a urine pregnancy test and you will be asked if you have experienced any medical events. Your subject card that has information about the clinical trial will be collected.

Here is a chart of the study visits with planned examinations:

Visits	**Visit 1a (Screening)**	**Visit 1b**	**Visit 2**	**Visit 3**	**Visit 4**	**Visit 5**	**Visit 6[1]**	**Visit 7 (Follow-Up)**
Study Drug Cycle			**1**	**3**	**6**	**9**	**13**	**10-14 days after Visit 6**
			Day 20 ± 2 of study drug cycle				**Day 29 + 2**	
Physical/gynecological examination[2]	x				x		x	
Blood pressure, pulse, weight, height (Visit 1a only)	x	x	x	x	x	x	x	
Blood sample for safety laboratory tests[3]	x		x[4]	x[3]	x	x[3]	x	
Blood sample for pharmacokinetic analysis			x		x			
Urine sample (dipstick)	x				x		x	
Pregnancy test (blood)	x							
Pregnancy test[5] (urine)		x	x	x	x	x	x	x
E-diary hand out		x[6]						
Study drug hand out		x	x	x	x	x		
Bring e-diary to the site			x	x	x	x	x	
Bring study drug to the site (incl. empty blisters)			x	x	x	x	x	
Study drug acceptability				x			x	
Consecutive contraception method						x[7]		
Assessment of well-being/medical events	x	x	x	x	x	x	x	x

1 or Early Discontinuation Visit.

2 Gynecological examination: inspection of the external genital organs, a speculum examination, the palpation of the internal genital organs and the examination of your breasts. Additionally, a transvaginal ultrasound and a cervical swab will be performed (only at Visit 1a and Visit 6).

3 Only electrolytes.

4 Only blood potassium if you take medications that may increase potassium blood level.

5 In addition, you will perform a urine dipstick pregnancy test at home at the beginning of each new study drug cycle. In case of a positive urine pregnancy test, a serum (blood) pregnancy test has to be done for confirmation.
6 Once you receive the e-diary, you will actively complete one training section.
7 Consecutive contraceptives should be started after last intake of study drug and should be used at least until Visit7/Follow-up. This arrangement is outside the trial and costs will not be covered by the sponsor.

Study Drug
If you are enrolled in the study, you will receive a cardboard blister pack with study drug for each cycle. Each pack will contain 28 tablets. The packs will include 24 white tablets (numbers 1-24) containing LF111 (4 mg drospirenone, also called DRSP) and 4 green tablets (numbers 25-28) without active drug ("placebo"). All tablets in each pack should be taken in the numbered order with no doses skipped. There will be no break between packs. When you finish taking the tablets in the pack for one cycle, on the next day you should take the first tablet in the next pack. Please enter the date and week day of your first dose that you take from each blister pack in the fields provided in the e-diary. The tablets should be swallowed whole at about the same time every day so that the interval between doses is approximately 24 hours.

To ensure reliable contraception throughout the study drug cycles, it is very important to take the green placebo tablets at the end of the cycle as indicated and not at the beginning or in between.

When starting a new oral contraceptive, you have to start with the first tablet on the first day of your menstrual bleeding. If your menstrual bleeding starts in the evening and you prefer to take the pill in the morning, then you can begin with the first tablet the next day (Day 2 of your menstrual bleeding). The doctor will explain it to you in detail.

If you switch directly from another contraceptive pill, you have to take the first tablet of the study drug on the day following the last active tablet of your previous hormonal contraceptive.

The bleeding is expected to start around two to four days after the intake of the last white LF111 tablet. It is possible that the bleeding may persist into the next study drug cycle, but you should continue to take the study drug as planned. If you have forgotten to take a white LF111 pill at the usual time, it must be taken as soon as you remember and within 24 hours of your scheduled dose. The next tablet should be taken at the usual time.

If you are more than 24 hours late in taking a white LF111 pill, it is important that you use additional contraceptive methods (e.g., a condom or a diaphragm) for the next seven days. In such a case, take the tablet as soon as you remember. Take the next one on time, even if that means taking up to two tablets at the same time, and continue taking the remaining tablets from the current blister as scheduled to avoid premature bleeding.

In case more tablets have been forgotten, the site staff will give you instructions on how to take the next tablet correctly.

If you forgot to take a green placebo tablet just skip the forgotten tablet and proceed with intake as scheduled on the next day. The forgotten intake of a placebo tablet has no impact on the contraception and no further measures like use of condoms are necessary.

You can contact the study doctor or staff any time if you have any questions about taking the study drug (for example, if you have missed a dose and are not sure which tablet to take next).

How to Perform the Pregnancy Test
You will be provided with a home pregnancy test, which has to be used at the beginning of each new study drug cycle.

The urine sample for the test can be obtained at any time of the day. However, it is recommended to use the first urine in the morning.

The urine has to be collected in a clean, dry container. Before testing the urine sample, it must have reached room temperature (59-86 °F).

Open the pouch only immediately before performing the test. (Do not use test devices that have become wet or have a damaged pouch.)

Remove the test kit from the sealed pouch. Place it on a clean, dry, flat surface. Use the plastic pipette supplied, hold vertically and add 4 drops of well-mixed urine to the round sample well. (The sample well is round, the results window is rectangular.)

Wait for the pink colored bands to appear. The test result (T) can then be read in the test window. Positive results may be observed in as little as 40 seconds depending on the concentration of HCG in the specimen. However to confirm negative results, the complete reaction time of 5 minutes is required. It is important that the background is clear before the result is read. Do not interpret the results after 10 minutes.

<u>Interpretation of results:</u>

Positive/pregnant: The test is positive if one distinct colored line appears in the T (test) window and one colored line appears in the C (control) window. The intensity of the color may vary.

Negative/not pregnant: The test is negative if a distinct colored line appears only in the C (control) window.

Invalid: The test is invalid if no line appears in the C (control) window even if a line appears in the T (test) window. This test should be repeated using another device.

Negative:



Positive:



Invalid:



Expectations for Study Participants
If you take part in this study you will be expected to:

(1) Provide a complete medical history and answer all questions truthfully.
(2) Tell the study doctor or staff in advance if you plan to undergo any other medical treatments during this clinical study, or are taking any medications.
(3) Attend all visits and complete the electronic diary daily.
(4) Notify the study doctor immediately if you suffer from any injury or unexpected reaction while you are in the study or if you think you might be pregnant.
(5) Take the study drug as required and bring the study drug and packaging (including empty blister cards) to each study visit.
(6) Be willing to have sexual intercourse in each study drug cycle.
(7) Answer a few medical questions on your male sexual partner(s) truthfully, to the best of your knowledge.

Further, you may not participate in another clinical study at the same time. You cannot participate in this clinical study if you have participated within the last 90 days in another clinical research study. If you gave birth to a child recently, you can only participate if you are not breastfeeding and have had 3 complete menstrual cycles since delivery.

If you need to take any other medications or supplements other than the study drug, please tell the study doctor or staff so they can advise you if further contraceptive measures (such as condoms, female condoms, cervical caps, diaphragms with or without spermicides, or contraceptive sponges) have to be used during this study drug cycle.

By signing this consent form, you are not giving up any of your legal rights as a study participant.

What are the risks and discomforts of the study?
LF111 is an investigational contraceptive drug and there is a risk that it might not be as effective as other oral contraceptives that are already on the market. Therefore, there is a risk that you might get pregnant during the study.

As with any other drug, this study drug has the potential to cause side effects. These effects can vary from symptoms that cause you mild discomfort to more severe conditions that will require treatment.

The side effects of DRSP (the active ingredient in LF111) given alone are not fully known. When given in combination with approved medications that contain ethinyl estradiol or estradiol, the most common events reported in more than 1% of subjects taking part in previous clinical studies include the following:

- Upper respiratory infection, headache, breast pain, vaginal yeast infection (moniliasis), vaginal discharge (leukorrhea), diarrhea, nausea, vomiting, vaginitis, abdominal pain, flu syndrome, painful menstruation (dysmenorrhea), allergic reaction, urinary tract infection, accidental injury, bladder infection (cystitis), tooth disorder, sore throat (pharyngitis), infection, fever, surgery, sinusitis, back pain, emotional lability, migraine, abnormal Pap smear (microscopic examination of cervical cells), indigestion (dyspepsia), rhinitis, acne, gastric flu (gastroenteritis), bronchitis, inflammation of the throat (pharyngitis), skin disorder, intermenstrual bleeding, libido decreased, weight gain, pain, depression, cough increased, dizziness, menstrual disorder, pain in extremity, pelvic pain, and weakness (asthenia).
- The use of combination oral contraceptives is associated with increased risks of several serious conditions, including venous and arterial thrombosis (formation of a blood clot in the vessel) and thromboembolic events (the event of a blood clot in a blood vessel that breaks loose and is carried in the bloodstream to plug another vessel). Examples of such events are myocardial infarction (heart attack), thromboembolism, or stroke. Risks of other potentially serious conditions include liver tumor, gallbladder disease, and high blood pressure. The risk of serious or life-threatening effects is very small in healthy women without underlying risk factors. The risk of serious or life-threatening events increases significantly in women who have other underlying risk factors, such as high blood pressure, high cholesterol levels, obesity, diabetes, and smoking. The risk of venous thromboembolic events with the use of DRSP alone is not yet known. However, preliminary results from an FDA-funded study suggest an approximate 1.5-fold increase in the risk of blood clots for women who use drospirenone-containing products compared to users of other hormonal contraceptives.

If you do not understand the meaning of any of these side effects or if you would like more details about them or the risks involved please ask the study doctor or the study staff.

If you have unusual or severe symptoms, please contact your study doctor immediately. The symptoms will be evaluated by the study doctor, who will also decide whether you should stop taking the study drug.

While taking the study drug, occasional breakthrough bleeding between periods (for example, spotting) and missed periods may occur. Irregular bleeding occurs most often during the first few months of oral contraceptive use. Breakthrough bleeding between periods is usually temporary and usually has no medical significance. If it occurs during the study drug cycle, please continue taking the tablets regularly and as planned.

If menstrual bleeding continues or is as intense as your regular period, you should contact the study doctor. If you miss more than one bleeding cycle, you should contact the study doctor to make sure you are not pregnant before you continue taking the study drug.

Combined contraceptive pills (ones that contain both estrogen plus progestogen) are known to increase the risk of a serious and potentially life-threatening disease called deep vein thrombosis (DVT), which is a blood clot in a blood vessel, usually in the leg. **If you have any of the DVT symptoms listed below (especially if they happen suddenly), call your study doctor right away**:

- Swelling in one or both legs
- Pain or tenderness in one or both legs, which may occur only while standing or walking
- Warmth in the skin of the affected leg
- Red or discolored skin in the affected leg
- Visible surface veins
- Leg fatigue

If a blood clot breaks free and travels to your lungs, it is called a pulmonary embolism, and it can cause death within hours. Pulmonary embolism may not cause symptoms, but if you ever suffer sudden coughing, which may bring up blood; sharp chest pain; rapid breathing or shortness of breath; or severe lightheadedness, call 911 or go to an emergency room immediately.

The risk of DVT and pulmonary embolism with the use of the study drug is low, but not yet known. Nevertheless, it has been shown that the risk of DVT and pulmonary embolism with the use of drospirenone-containing oral pills may be slightly higher than with other oral contraceptives: 10.22 per 10,000 woman years versus 3-9 per 10,000 woman years.

The contraceptive effectiveness of the study drug (LF111) may be decreased by using other medications at the same time that affect the metabolism of hormones in the body so that the hormones are not as effective as usual. The medications with these effects include (but are not limited to) barbiturates, rifampicin, griseofulvin, phenylbutazone, and antiepileptic agents (such as barbexaclone, carbamazepine, phenytoin, primidone).

Reduced effectiveness of the study drug can also be expected when using broad spectrum antibiotics (such as ampicillin or tetracyclines), after taking St. John's wort, or after taking activated charcoal (3 hours before or after taking the charcoal).

Since the study drug contains drospirenone, it can increase potassium blood levels. Too much potassium in your blood can cause dangerous or life-threatening changes in heart rhythm. Other drugs may also increase potassium blood levels, such as spironolactone, potassium supplementation, ACE inhibitors, angiotensin-II receptor antagonists, and heparin. Therefore, if you take any other medications or supplements during the study, please tell your doctor or the study staff so that they can let you know if you should stop taking the study drug or if further contraceptive measures like condoms or a diaphragm have to be used during this study drug cycle.

Insulin or oral antidiabetic requirements may be altered due to the possible effect of oral contraceptives on glucose tolerance.

In the event of vomiting or intestinal disease like diarrhea, taking the tablets should not be interrupted. Additional contraceptive methods (such as a condom or a diaphragm) must be used for the next seven days if vomiting or diarrhea has taken place in the first 3 to 4 hours after taking an LF111 tablet.

Please note that LF111, like currently marketed oral hormonal contraceptives, does not protect you from infection with HIV or other sexually transmitted diseases.

Please show your subject card, which documents that you are participating in this study, at any time you have a medical treatment at some other location. If treated by another doctor, please inform your study doctor as soon as possible.

You may feel discomfort during some of the tests. These discomforts and risks include the blood draws and physical examinations:

- Blood draws: When a blood sample is taken, there may be some discomfort and bruising at the site where the needle is inserted through the skin. There is a possibility of fainting, and there is a possibility of bruising or infection at the insertion site.
- Gynecological examinations: The transvaginal ultrasound examination may cause a little discomfort for you, as well the speculum examination, the palpation of your internal organs, and the examination of your breasts, but they usually do not hurt.

Unforeseen Risks

There is a risk of rare or previously unknown side effects from the study drug. Your study doctor will inform you about any significant new findings that may occur during this study, which may affect your decision to remain in the study.

Pregnancy and Birth Defects
Taking the study drug may involve unknown risks to a pregnant woman, an embryo, a fetus (unborn baby), or a nursing baby. Therefore, if you are pregnant, planning to become pregnant, or are breastfeeding a child, you cannot participate in this study.

If you become pregnant or suspect that you are pregnant during this clinical study, please inform your study doctor immediately. If you are pregnant, you have to stop the study drug immediately. Your doctor will follow your pregnancy to its outcome. Also, pregnancies within three months after exiting the study have to be reported to the study doctor.

What are the potential benefits?
Drosperinone may prevent pregnancy when used properly; however, there is no guarantee. Information learned from the study may help others in the future.

What other options are available?
You do not have to be in this study to receive contraception. Alternative contraceptive treatments that are available include: other birth control pills, intrauterine devices (with or without a hormone), condoms, hormonal implants, injectable hormones, diaphragms, spermicides, female condoms, cervical caps, and contraceptive sponges. Also, other birth control methods, such as the rhythm or temperature method, are known. Each method has different reliability for preventing pregnancies, as well as different risks and advantages. Please ask your study doctor if you need more information.

Will I be paid to participate in this study?
You will be paid for each completed study visit. If you complete all visits, you will be paid a total of $775.00. You will be paid as follows:

Visit 1a: $50.00
Visit 1b: $75.00
Visit 2: $75.00
Visit 3: $75.00
Visit 4: $100.00
Visit 5: $100.00
Visit 6: $150.00
Visit 7: $150.00

Costs
There will be no cost to you for your participation in this research study.

What will happen if i am injured in this study?
Laboratorios León Farma S.A. has taken out insurance coverage in accordance with the requirements in your country.

Insurance company: Medmarc Insurance Group, 14280 Park Meadow Drive, Suite 300, Chantilly, VA 20151-2219 (Policy no. N14NC380021)

Details and information about the insurance coverage for study-related injury can be provided by the study doctor.

Any impairment of health which may be due to participation in this clinical study must be reported to your study doctor immediately.

If you get hurt because you are participating in the study and you need medical care, the study doctor will help you get the care you need right away. You will not have to pay for any emergency care expenses that are directly related to conditions caused by the study. No funds have been set aside to pay for any other medical care. The study doctor will talk with you about any medical problems you may have. He or she may send you to other doctors for medical care. If you have questions, talk with your study doctor.

IF YOU HAVE A MEDICAL EMERGENCY: If you are having a serious medical problem, you are advised to call your primary care provider, immediately go to the nearest emergency room, or call 911. Please report this event or any life-threatening health problem to the study doctor as soon as possible after you have received the necessary medical care.

Unwanted pregnancy does not represent damage to health in the context of this study. Thus, there will be no compensation for any unwanted pregnancy or for health problems of the unborn or new born baby.

What if I want to leave the study, or I am asked to withdraw from the study?
Taking part in this research study is voluntary. You have the right to choose not to take part or to stop participating at any time. There will be no penalty or loss of benefits if you choose not to participate or decide to stop participating at any time. However, if you choose to stop participation in this research study, you will be asked to notify the study doctor or study staff, return study drug, and return for Visit 6/Early Discontinuation Visit for final procedures. If you do not wish to take part in this research study or later withdraw from it, this will not affect your future care.

If you decide to withdraw, your study doctor will help you make arrangements for your future care. In addition, your study doctor may withdraw you from the study if he or she thinks it is in the best interest of your health. If this happens, he or she will explain the reason and arrange for your care to continue.

You may also be withdrawn from the study if you do not follow the study doctor's directions or if your health condition changes in a way that staying in the study may risk your health or the outcome of the study. The entire study can also be discontinued at any time by the study doctor, by the sponsor (Laboratorios León Farma S.A.), the Copernicus Group Independent Review Board (IRB) or by a regulatory authority (such as the FDA).

New Findings
Any new important information that is discovered during the study that may change your decision to stay in the study will be given to you in a timely manner.

Confidentiality of Records
The information that is necessary for the analysis and evaluation of the trial will not identify you by name but by a subject number that will be assigned to you and your date of birth. If the results of the trial are published, your identity will remain confidential.

Confidentiality will be maintained by the applicable laws and regulations and study records will not be made publicly available. This confidentiality will apply unless the law or FDA requires disclosure of otherwise confidential information. Representatives of Laboratorios León Farma S.A., HDI or Scope International AG may inspect your original medical records and study records to assess compliance with the study protocol and all regulations. The FDA and IRB may also inspect these records. By signing this document, you consent to such inspection and you allow the FDA, representatives of Laboratorios León Farma S.A., HDI, Scope International AG and the Copernicus Group IRB to have access to your original medical and study records.

A description of this clinical trial will be available on *http://www.ClinicalTrials.gov*, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

You also agree that Laboratorios León Farma S.A. has the full ownership of the original case report forms (documents where the results of the tests you undergo are written anonymously) completed as part of the study. Data obtained from the study may be published in medical journals and presented at international meetings. In such cases, you will not be identified so that confidentiality can be maintained.

Electronic Medical Records and Research Results

What is an Electronic Medical Record?

An Electronic Medical Record (EMR) is an electronic version of the record of your care within a health system. An EMR is simply a computerized version of a paper medical record.

If you are receiving care or have received care within the University of Pennsylvania Health System (UPHS) (outpatient or inpatient) and are participating in a University of Pennsylvania research study, results of research-related procedures (i.e. laboratory tests, imaging studies and clinical procedures) may be placed in your existing EMR maintained by UPHS.

If you have never received care within UPHS and are participating in a University of Pennsylvania research study that uses UPHS services, an EMR will be created for you for the purpose of maintaining any results of procedures performed as part of this

research study. The creation of this EMR is required for your participation in this study. In order to create your EMR, the study team will need to obtain basic information about you that would be similar to the information you would provide the first time you visit a hospital or medical facility (i.e. your name, the name of your primary doctor, the type of insurance you have). Results of research procedures performed as part of your participation in the study (i.e. laboratory tests, imaging studies and clinical procedures) may be placed in this EMR.

Once placed in your EMR, these results are accessible to appropriate UPHS workforce members that are not part of the research team. Information within your EMR may also be shared with others who are determined by UPHS to be appropriate to have access to your EMR (e.g. health insurance company, disability provider, etc).

Contacts
You may contact the following persons for answers to any questions or concerns you have during the study:

Kurt T. Barnhart, MD, MSCE (Study Principal Investigator)
215-662-7727

Please call Copernicus Group IRB at 1-888-303-2224 if:

- You want to talk to someone other than the study doctor or study staff
- You have a hard time reaching the study doctor or study staff
- You have questions about your rights as a research subject

Please visit the Copernicus Group IRB website www.cgirb.com for more information about research studies and the role of a research subject.

For questions about the study/or if you have a study related injury please contact your study doctor (please refer to the first page).

For emergency and/or after hours questions please contact your study doctor (please refer to the first page).

In the event that you experience any adverse reaction to the study drug or procedures during the course of this study, you should immediately contact your study doctor (see first page).

SUBJECT'S STATEMENT OF INFORMED CONSENT

Study Title: A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

Study Code: CF111/303

Name of Subject: _____
(full name of the participant), hereby declares by signing this informed consent form that:

I have read and understand the information in this informed consent document. I have had an opportunity to ask questions and all of my questions have been answered to my satisfaction. I voluntarily agree to participate in this study. I do not give up any of my legal rights by signing this consent document. I will be given a copy of this signed consent form before any study related procedures are performed.

I agree that my general practitioner or personal doctor may be informed by the study doctor about my participation in this study. Initial beside your choice below:

YES_____ NO_____

I agree that my general practitioner or personal doctor may send my previous medical records to the trial doctor. Initial beside your choice below:

YES_____ NO_____

I hereby freely consent to take part in the study.

1) _____ _____ _____
Subject's Printed Name | Subject's Signature | Date

The information about the study was described to the subject in a language she understood.

2) _____ _____ _____
Printed Name of Person Obtaining Consent | Signature of Person Obtaining Consent | Date

A copy of the signed subject informed consent and authorization form must be provided to the subject.

AUTHORIZATION FOR USE AND DISCLOSURE OF HEALTH INFORMATION

Federal Privacy Regulations provide safeguards for privacy, security, and unauthorized access or use of identifiable health information. As part of the study, the study doctor or the study staff may disclose study related information including demographic information, the study exams and results of tests described in this consent form, past and present medical records (including medical record numbers, name, address, date of birth, telephone number, email address), and research records to the United States Food and Drug Administration (FDA) and representatives from Laboratorios León Farma S.A., Health Decisions, Inc. (HDI), Scope International AG, and any laboratories used for this study. Your records may be reviewed by the FDA, representatives of Laboratorios León Farma S.A., Health Decisions, Scope International AG, other governmental agencies, or the Copernicus Group Independent Review Board (IRB). The IRB is a group of people who perform independent review of research. Your records may also be reviewed by the University of Pennsylvania Office of Clinical Research, or authorized members of the workforce of the University of Pennsylvania Health System who may need access to your information to carry out their job functions (examples: billing department, patient registration).

Identifiable information about you and your health may be disclosed to the parties listed above for research, study research results, and payment purposes. The information may also be used and disclosed at the request of the FDA, representatives from Laboratorios León Farma S.A., HDI and Scope International AG, and the IRB. This information may also be used and disclosed to comply with reporting requirements of these parties and with applicable laws.

When the information is disclosed, it may no longer be protected by the Federal Privacy Regulations and it may be re-disclosed to other parties.

Although the Federal Privacy Regulations provide individuals with the right to access and inspect health information collected from or created about them, access to this information may be temporarily suspended for as long as the research study is in progress. By signing this authorization, you are agreeing to this temporary restriction, but your right to access these records will be given back upon completion of this research.

This Authorization does not have an expiration date. If you do not withdraw this Authorization in writing, it will remain in effect indefinitely. Your study doctor will keep this Authorization for at least 6 years.

If you refuse to sign this authorization, you will not be permitted to participate in this study or receive research-related treatment. If you revoke or cancel the authorization to use and disclose your health information, the information that has already been obtained or created will still be used and disclosed, if necessary, to preserve the reliability of the research. If you withdraw your permission, no new health information will be gathered unless you have a side effect related to the study. The cancellation of this authorization will only affect identifiable health information that is obtained after the study doctor has received the notice in writing. If you withdraw from the study but do not withdraw your Authorization, new health information may be collected until this study ends.

If you decide to withdraw the authorization to use your personal information, you must contact your study doctor (please refer to the first page) in writing and indicate that you are withdrawing the right to the use of your personal information. If you withdraw your permission, you will not be able to continue being in the research study.

Your decision to withdraw your Authorization or not to participate will not involve any penalty or loss of access to treatment or other benefits to which you are entitled,

AUTHORIZATION

By signing this form, I allow the use or disclosure of my health information. I will receive a signed and dated copy of this Authorization.

_____	_____	_____
Subject's Printed Name	Subject's Signature	Date